Tag Archives: Myeloma

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Blenrep approved by US FDA for use in treatment of relapsed/refractory multiple myeloma

Significant unmet need for patients requires new and novel treatments1 DREAMM-7 showed a 51% reduction in the risk of death and tripled median progression-free survival in 3L+ indicated population versus a daratumumab-based triplet2 Blenrep is the only anti-BCMA accessible in the community setting where 70% of patients receive care, and with a new streamlined REMS programme3 Robust clinical development is …

Read More »